文献速递术前评估与围术期医学气道管理

重症监护与麻醉中的高流量鼻导管氧疗

High-flow nasal oxygen therapy in intensive care and anaesthesia.
PubMed 文献 · Br J Anaesth · 2017-11-21

本文综述高流量鼻导管氧疗(HFNO)在重症监护与麻醉中的应用。HFNO可提供加温湿化、可滴定的氧疗,满足或超过患者吸气需求,机制包括冲洗咽部死腔、降低气道阻力、产生呼气末正压及增强氧输送。HFNO对多种病因的低氧性急性呼吸衰竭可改善氧合,并可能减少气管插管需求及延长插管期间无呼吸氧合时间,但适应证与失败因素仍需大型队列研究明确。

要点

  • HFNO可改善多数低氧性急性呼吸衰竭患者的氧合。
  • HFNO可能减少拔管后呼吸衰竭患者的气管插管需求。
  • HFNO可延长插管期间无呼吸氧合时间以减少氧饱和度下降。

核心结论

  • HFNO是低氧性急性呼吸衰竭的替代氧疗方式,对多数患者可改善氧合。
  • HFNO可能减少拔管后急性呼吸衰竭患者的气管插管需求。
  • HFNO在插管期间可延长无呼吸氧合时间以减少氧饱和度下降。
  • HFNO的适应证、禁忌证及失败相关因素尚需大型队列研究明确。

研究设计与样本

  • 本文为综述,总结HFNO在重症监护与麻醉中应用的现有证据。

主要发现

  • HFNO提供加温湿化、可滴定的氧疗,匹配或超过患者吸气需求。
  • HFNO的作用机制尚未完全明确,可能包括咽部死腔冲洗、降低气道阻力、产生呼气末正压及增强氧输送。
  • 新兴证据提示HFNO对多种病因的低氧性急性呼吸衰竭可改善氧合。
  • HFNO在重症监护与手术室插管期间可延长无呼吸氧合时间。

临床怎么用

  • 对低氧性急性呼吸衰竭患者可考虑HFNO作为传统氧疗的替代。
  • 拔管后急性呼吸衰竭患者可考虑HFNO以减少再插管需求。
  • 插管期间可考虑HFNO延长无呼吸氧合时间以减少氧饱和度下降。
  • 应用HFNO时需关注其失败风险,适应证与禁忌证尚待明确。

局限性

  • HFNO的作用机制与生理效应尚未完全明确。
  • HFNO的适应证、禁忌证及失败相关因素尚需大型队列研究明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Oxygen therapy is first-line treatment for hypoxaemic acute respiratory failure (ARF). High-flow nasal oxygen therapy (HFNO) represents an alternative to conventional oxygen therapy. HFNO provides humidified, titrated oxygen therapy matching or even exceeding the patients' inspiratory demand. The application of HFNO is becoming widespread in Intensive Care Units (ICUs), favoured by increasing evidence based on numerous studies supporting its efficacy. The mechanisms of action and physiological effects of HFNO are not yet fully understood. Pharyngeal dead space washout, decrease in airway resistance, generation of a positive end-expiratory pressure, and enhanced delivery of oxygen are all alleged to be potential mechanisms. The emerging evidence suggests that HFNO is effective in improving oxygenation in most patients with hypoxaemic ARF of different aetiologies. Notwithstanding the potential benefit of HFNO in the management of hypoxaemia, further large cohort studies are necessary to clarify the indications, contraindications and factors associated with HFNO failure. HFNO may also be valuable in reducing the need for tracheal intubation in the management of post-extubation ARF. In addition, HFNO has been proposed to limit oxygen desaturation by prolonging apnoeic oxygenation during intubation both in ICUs and operating theatres.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Renda T, Corrado A, Iskandar G, et al. High-flow nasal oxygen therapy in intensive care and anaesthesia. Br J Anaesth. 2017. PMID: 29397127. doi:10.1016/j.bja.2017.11.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。